Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy

INTRODUCTION: To examine treatment persistence and clinical outcomes associated with switching from a tumor necrosis factor inhibitor (TNFi) to a medication with a new mechanism of action (MOA) (abatacept, anakinra, rituximab, tocilizumab, or tofacitinib) versus cycling to another TNFi (adalimumab,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wenhui, Knapp, Keith, Wang, Li, Chen, Chieh-I, Craig, Gary L., Ferguson, Karen, Schwartzman, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565674/
https://www.ncbi.nlm.nih.gov/pubmed/28674959
http://dx.doi.org/10.1007/s12325-017-0578-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565674/
https://www.ncbi.nlm.nih.gov/pubmed/28674959
http://dx.doi.org/10.1007/s12325-017-0578-8

Ejemplares similares